-

Rosen Law Firm Urges Synopsys, Inc. (NASDAQ: SNPS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, both dates inclusive (the “Class Period”). Synopsys provides electronic design automation software products used to design and test integrated circuits.

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Synopsys, Inc. (NASDAQ: SNPS) Misled Investors Regarding its Business Operations.

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) the extent to which Synopsys’ increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, “certain road map and resource decisions” were unlikely to “yield their intended results,”; (3) that the foregoing had a material negative impact on financial results; and (4) as a result of the foregoing, defendants’ positive statements about Synopsys’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Synopsys, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by December 30, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:SNPS

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

More News From Rosen Law Firm

JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors there is a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025. Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Jasper Therapeutics, Inc...

Rosen Law Firm Encourages Nidec Corporation Investors to Inquire About Securities Class Action Investigation – NJDCY

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Nidec Corporation (OTC: NJDCY) resulting from allegations that Nidec Corporation may have issued materially misleading business information to the investing public. So What: If you purchased Nidec Corporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency...

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Five Below, Inc. – FIVE

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Five Below, Inc. (NASDAQ: FIVE). If you currently own shares of Five Below stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=27613 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We enc...
Back to Newsroom